期刊文献+

新规格阿仑膦酸钠治疗老年骨质疏松症30例 被引量:4

Analysis of new specification alendronate in treating senile osteoporosis
下载PDF
导出
摘要 目的观察新规格阿仑膦酸钠治疗老年骨质疏松的疗效及安全性。方法老年骨质疏松病人61例,随机分为2组,治疗组男性10例,女性20例,年龄(78±s 4)a,每周口服阿仑膦酸钠1片(70 mg),同时口服骨化三醇0.25μg·d^(-1);对照组男性11例,女性20例,年龄(77±6)a,仅服骨化三醇,疗程均为6 mo。观察2组骨骼疼痛情况及骨密度变化。结果治疗后,治疗组骨骼疼痛改善有效率87% (26/30),对照组65%(20/31),2组比较差异显著(P<0.05)。治疗组除华氏三角区外各部位骨密度均较治疗前上升,提高骨密度的有效率达73%(22/30),对照组为45%(14/31),2组间比较,差异有显著意义(P<0.05)。治疗前后2组三大常规,肝、肾功能等均无明显改变,无明显不良反应。结论新规格阿仑膦酸钠治疗老年骨质疏松安全、有效。 AIM for senile osteoporosis. To evaluate the clinical therapeutic effect and safety METHODS Sixty-one senile osteoporotic patients of new specification alendronate were randomly divided into two groups, 30 patients (M 10, F 20, age (78 ± s 4) a) in the treatment group and 31 patients (M 11, F 20, age (77 ± 6) a) in the control group. The patients in the treatment group were treated with alendronate 70 mg· wk^-1 and calcitriol 0.25 μg·d^-1, while the patients in the control group with calcitriol 0.25 μg·d^-1 only, both for 6 mo as a course. The changes of bone pain and bone mineral density (BMD) were closely observed. RESULTS After the therapy, pain alleviated efficacies of treatment group and control group were 87 % (26/ 30) and 65 % (20/31), with significant difference (P 〈 0.05). The BMD of the treatment group increased except that in Ward's angle area, to the average efficiency BMD of 73 % (22/30) , however, the control group increased the average efficient BMD of 45 % (14/31), showing significant difference between the two groups (P 〈 0.05 ). Biochemical levels of the three main routines, hepatic and renal functions of the two groups revealed no perceivable change. CONCLUSION Alendronate is effective and safe for treatment of senile osteoporosis.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第2期93-95,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 阿仑膦酸 骨质疏松 骨密度 alendronic acid osteoporosis bone density
  • 相关文献

参考文献11

  • 1HOCHBERG MC,RIZZOLI R. Long-term experience with alendrohate in the treatment of osteoporosis [J]. Expert Opin Pharmacother, 2006, 7(9): 1201-1210.
  • 2HOUGH S. NOFSA statement on generic bisphosphonates[J]. S Afr Med J, 2006, 96(9):758-760.
  • 3KANIS JA, MELTEN LJ 3rd, CHRISTIOANSEN C, et al. The diagnosis of osteoporosis[J]. J Bone Miner Res, 1994,9(8):1137-1141.
  • 4王宁华.疼痛定量评定的进展[J].中国临床康复,2002,6(18):2738-2739. 被引量:461
  • 5李正翔.骨质疏松症的药物治疗进展[J].天津药学,2003,15(3):59-61. 被引量:10
  • 6CHESNUT CH, McCLUNG MR, ENSRUD KE, et al. Alendrohate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling[J]. Am J Med, 1995, 99(2): 144-152.
  • 7SHARPE M, NOBLE S, SPENCER CM. Alendronate: an update of its use in osteoporosis[J]. Drugs, 2001, 61(7):999-1039.
  • 8徐尚忠,毛旭东,周薇.阿仑膦酸钠对老年女性骨质疏松症的疗效[J].中国新药与临床杂志,2000,19(4):289-290. 被引量:19
  • 9LIBERMAN UA, WEISS SR, BROLLJ, etal. Effect of oral Mendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis[J]. N Engl J Med, 1995, 333(22): 1437-1443.
  • 10DONAHUE JG, CHAN KA, ANDRADE SE, et al. Gastric and duodenal safety of daily alendronate[J]. Arch Intern Med, 2002, 162(8):936-942.

二级参考文献31

  • 1石元俊.原发性骨质疏松症的研究进展[J].中国临床新医学,1999,12(3):209-217. 被引量:2
  • 2[1]FISAHMAN B,PASTERNAK S,WALLENSTEIN SL,et al.The memorial pain assessment card[J].Cancer,1987,60:1151- 1158.
  • 3[2]RHIND VM,BIRD NA, WRIGHT V.A comparison of clinical assessment of disease activity in rheumatoid arthritis[J].Annals of the Rheumatic Disease,1980,39:135- 137.
  • 4[3]HUSKISSON EC,JONE J,SCOTT PJ.Application of visual analogue scales to the measurement of functional capacity[J].Rheumatology and Rehabilitation,1976,15:185- 187.
  • 5[4]DOWNIE WW,LEATHAM PA,RHIND VM.Studies with pain rating scales[J].Annals of the Rheumatics Diseases,1978, 37: 378- 381.
  • 6[5]WILKIE D,LOVEJOY N,DODD M,et al.Cancer pain intensity measurement:concurrent validity of three tools- finger dynameter,pain intensity number scale, visual analogue scale[J].Hospice Journal,1990, 6:1- 13.
  • 7[6]MARCHAND S,BUSHNELL MC,DUNCAN GH.Modulation of heat pa- in perception by high frequency transcutaneous electrical nerve stimulation (TENS)[J].Clinical Journal of Pain,1991,1: 122- 129.
  • 8[7]PRICE DD,BUSH FM,LONG S,et al.A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scale[J].Pain,1994, 56: 217- 226.
  • 9[8]JESEN MP,MCFARLAND CA.Increasing the reliability and validity of pain intensity measurement in chronic pain patients[J].Pain,1993,55:195- 203.
  • 10[9]RANSFORD AO, CAIRNS D,MOONEY V.The Pain drawing as an aid to the psychological evaluation of patients with low- back pain[J].Spine,1976,1(2):127- 134.

共引文献485

同被引文献17

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部